. 2021 Dec 10;2021(1):275-280. doi: 10.1182/hematology.2021000259

Table 2.

Sociodemographic and center factors associated with outcomes of allogeneic HCT

Reference^a	Population	Variable(s)	Key findings
Bona et al²⁸	Age ≤18 years; all diagnoses; first allogeneic HCT recipients reported to CIBMTR; 2006-2015	SES	In children with malignant disease, high neighborhood poverty level associated with higher NRM and Medicaid insurance status associated with higher NRM and inferior OS (vs private insurance); no association between neighborhood poverty and HCT outcomes for nonmalignant disease
Hong et al⁸	Age ≥18 years; all diagnoses; first allogeneic HCT recipients reported to CIBMTR; 2014-2016	Several (county-level indicators of community health)	Patients residing in counties with worse community health status had inferior OS; among patients with hematologic malignancy, worse community health status was associated with inferior OS and higher risks of NRM
Madbouly et al²⁹	All ages; all diagnoses; allogeneic HCT using 10/10 allele matched MUD reported to CIBMTR; 1995– 2001	Race/ethnicity (ancestry)	Higher recipient-donor African genetic admixture associated with lower OS and DFS and higher NRM
Majhail et al¹⁶	Adult HCT centers; all diagnoses; allogeneic HCT reported to CIBMTR; 2008-2010 and 2012– 2014	Center volume	Higher 100-day and 1-year OS in high-volume (>40 allogeneic HCT/year) vs low-volume centers; presence of survivorship program associated with higher 1-year OS
Khera et al³⁰	Adult; all diagnoses; first allogeneic HCT recipients at single center; 2000-2010	Geography (distance from HCT center)	No association of distance and OS, NRM, or relapse; trend toward higher NRM with increased distance in nonmyeloablative HCT recipients
Bhatt et al³¹	All ages; hematologic malignancy; single-center study of first auto and allogeneic HCT recipients; 2007-2011	Time to insurance approval	Time to insurance approval for HCT varied between private and public payers but was not associated with OS

^{^a}

Table shows representative studies in US populations published since 2015.

DFS, disease-free survival; NRM, nonrelapse mortality; OS, overall survival.